维普中文期刊产品整合服务
19篇 您的检索式:作者名="LEEMANN T"
    题名 作者 年代 出处 被引量
1Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam 显示文摘Bonnabry P Leemann T Dayer P 1996Eur J Clin Pharmacol1996,49,4:1
2The role of rota- tion thromboelastometry in early prediction of massive transfu- sion显示文摘Leemann H Lustenberger T Talving P 2010J Trauma2010,69,6:1
3A severe complication after laser-induced damage to a transtracheal catheter during endoscopic laryngeal surgery 显示文摘Leemann B Heidegger T Grossenbacher R 2004Anesth Analg2004,98,6:1
4Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam显示文摘Bonnabry P Leemann T Dayer P 1996EurJ Clin Pharmacol1996,49,:1
5Cytokines and atherosclerosis: a comprehensive review o f studies in mice 显示文摘K leemann R Zadelaar S Kooistra T 2008Cardiovasc Res2008,79,3:1
6Influence of rifampin on fleroxacin pharmacokinetics显示文摘Schrenzel J Dayer F Leemann T 1993Antimicrob Agents Chemother1993,37,10:1
7Cytokines and atherosclerosis:a comprehensive review of studies in mice显示文摘leemann R Zadelaar S Kooistra T 0,,03:1
8Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam显示文摘Bonnabry P Leemann T Dayer P 1996Eur J Clin Phar- macol1996,49,4:1
9In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYlY2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors显示文摘TRANSON C LEEMANN T DAYER P 1996Eur J Clin Pharmacol1996,50,3:1
10In vitro comparative inhibi- tion profiles of major human drug metabolising cytochrome P450 isozymes (CYP2Cg, CYP2D6 and CYP3A4) by HMG- CoA reductase inhibitors显示文摘Transon C Leemann T Dayer P 1996Eur J Clin Pharmacol1996,50,:1
11Role of human liver mi-crosomal CYP2C9 in thebiotransformation of lomoxicam显示文摘Bonnabry P Leemann T Dayer P 1996Eur J Clin Pharmacol1996,49,4:1
12Quantitative drug interactions prediction system (Q-DIPS) :a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies 显示文摘Bonnabry P Sievering J Leemann T 2001Clin Pharmacokinet2001,40,9:1
13Cytochrome P450TB (CYP2C) : a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver显示文摘Leemann T Transon C Dayer P 1993Life Sci1993,52,1:1
14In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin显示文摘Transon C Leemann T Vogt N 1995Clin Pharmacol Ther1995,58,:1
15In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9,CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors显示文摘Transon C Leemann T Dayer P 1996Eur J Clin Pharmacol1996,50,:1
16Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration andeffect : influence of genetic status on behaviour of atenolol, bopin- dolol and metoprolol显示文摘Dayer P Leemann T Marmy A 1985Eur J Clin Pharmacol1985,28,2:1
17In vivo inhibition profile of cytochrome P450TB( CYP2C9 ) by ( + / - )-fluvastatin显示文摘Transon C Leemann T Vogt N 1995Clin Pharmacol Ther1995,58,4:1
18Role of human liver microsomal CYP2C9 in the biotransformation of lomoxicam显示文摘Bonnabry P Leemann T Dayer P 1996Eur J Clin Pharmacol1996,49,4:1
19In vivo inhibition profile of cytochrome P450TB (CYP2C9)by (+/-)-fluvastatin显示文摘TRANSON C LEEMANN T VOGT N 1995Clin Pharmacol Ther1995,58,4:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费